Calithera Biosciences Inc Quick Ratio (CALA) starting from the fourth quarter 2022 to fourth quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Calithera Biosciences Inc   (NASDAQ: CALA)

Calithera Biosciences Inc 's Quick Ratio

CALA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2022, Quick Ratio deteriorated to 3.44 a new company low.

Within Major Pharmaceutical Preparations industry 319 other companies have achieved higher Quick Ratio than Calithera Biosciences Inc in fourth quarter 2022. While Quick Ratio total ranking in the fourth quarter 2022 has deteriorated compared to the prior quarter from 981 to 1073.

Explain Quick Ratio?
How much Cash & cash equivalents CALA´s has?
What are CALA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CALA Quick Ratio (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1		 (Dec 31 2021)
Q4
Y / Y Current Liabilities Change -47.24 % -31.77 % -28.72 % -17.52 % -23.88 %
Y / Y Cash & cash equivalent Change -57.25 % -59.68 % -54.68 % -56.57 % -74.11 %
Quick Ratio MRQ 3.44 3.69 4.7 3.93 4.25
CALA's Total Ranking # 1073 # 981 # 864 # 990 # 926
Seq. Current Liabilities Change -19.95 % 3.8 % -21.81 % -18.78 % 3.52 %
Seq. Cash & cash equivalent Change -25.29 % -18.48 % -6.44 % -24.98 % -29.54 %



Quick Ratio fourth quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 320
Healthcare Sector # 537
Overall Market # 1073


Quick Ratio Statistics
High Average Low
25.16 9.51 3.44
(Mar 31 2015)   (Dec 31 2022)




Financial Statements
Calithera Biosciences Inc 's Current Liabilities $ 7 Millions Visit CALA's Balance sheet
Calithera Biosciences Inc 's Cash & cash equivalent $ 25 Millions Visit CALA's Balance sheet
Source of CALA's Sales Visit CALA's Sales by Geography


Cumulative Calithera Biosciences Inc 's Quick Ratio

CALA's Quick Ratio for the trailling 12 Months

CALA Quick Ratio

 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months		 (Dec 31 2021)
12 Months
Y / Y Current Liabilities TTM Growth -31.44 % -25.25 % -25.85 % -24.26 % -22.92 %
Y / Y Cash & cash equivalent TTM Growth -56.95 % -64.66 % -59.04 % -55.03 % -48.38 %
Quick Ratio TTM 3.96 4.14 4.82 5.47 6.3
Total Ranking TTM # 628 # 635 # 674 # 642 # 611
Seq. Current Liabilities TTM Growth -15.21 % -8.99 % -6.97 % -4.49 % -7.55 %
Seq. Cash & cash equivalent TTM Growth -18.93 % -21.88 % -17.95 % -17.16 % -33.45 %

Quick ratio ranking by company, industry and sector >> Back to CALA Financial Strength Comparisons >> Go to Compare CALA Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in CALA's Current Liabilities to $7.39 millions, cumulative Quick Ratio to 3.96 above the company average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 596 other companies have achieved higher Quick Ratio than Calithera Biosciences Inc . While Quick Ratio overall ranking has improved so far to 4447, from total ranking during the twelve months ending third quarter 2022 at 4466.

Explain Quick Ratio?
How much Cash & cash equivalents CALA´s has?
What are CALA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 597
Healthcare Sector # 1196
Within the Market # 1073


trailing twelve months Quick Ratio Statistics
High Average Low
11.1 3.86 1.43
(Sep 30 2015)   (Mar 31 2018)




Companies with similar Quick Ratio in the quarter ending Dec 31 2022, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2022 MRQ Cash & cash equivalentDec 31 2022 MRQ Current Liabilities
Moonlake Immunotherapeutics  9.41 $ 72.115  Millions$ 7.665  Millions
Alx Oncology Holdings Inc  9.40 $ 266.207  Millions$ 28.325  Millions
Viracta Therapeutics Inc   9.35 $ 91.043  Millions$ 9.733  Millions
Allakos Inc   9.31 $ 279.786  Millions$ 30.038  Millions
Point Biopharma Global Inc   9.30 $ 525.212  Millions$ 56.496  Millions
Enanta Pharmaceuticals Inc  9.25 $ 249.232  Millions$ 26.936  Millions
Structure Therapeutics Inc   9.24 $ 90.957  Millions$ 9.842  Millions
Day One Biopharmaceuticals Inc   9.22 $ 342.269  Millions$ 37.107  Millions
Citius Pharmaceuticals Inc   9.22 $ 41.750  Millions$ 4.530  Millions
Artelo Biosciences Inc   9.17 $ 9.150  Millions$ 0.998  Millions
Whitehawk Therapeutics Inc   9.16 $ 172.560  Millions$ 18.835  Millions
Dyne Therapeutics Inc   9.11 $ 256.012  Millions$ 28.088  Millions
Rocket Pharmaceuticals Inc   9.10 $ 356.394  Millions$ 39.169  Millions
Trevi Therapeutics Inc   9.01 $ 120.510  Millions$ 13.375  Millions
Moleculin Biotech Inc   8.95 $ 43.145  Millions$ 4.819  Millions
Erasca Inc   8.95 $ 435.620  Millions$ 48.690  Millions
Immunic Inc   8.90 $ 116.374  Millions$ 13.077  Millions
Clearside Biomedical Inc   8.88 $ 48.258  Millions$ 5.434  Millions
Cymabay Therapeutics Inc   8.77 $ 135.485  Millions$ 15.441  Millions
Chinook Therapeutics Inc   8.72 $ 378.325  Millions$ 43.387  Millions
Infinity Pharmaceuticals Inc   8.70 $ 38.313  Millions$ 4.405  Millions
Inozyme Pharma Inc   8.69 $ 127.866  Millions$ 14.715  Millions
Shuttle Pharmaceuticals Holdings Inc   8.63 $ 8.417  Millions$ 0.976  Millions
Disc Medicine Inc   8.62 $ 194.611  Millions$ 22.578  Millions
Pulmatrix Inc   8.59 $ 35.781  Millions$ 4.165  Millions
Capricor Therapeutics inc   8.41 $ 41.421  Millions$ 4.924  Millions
Oncternal Therapeutics Inc   8.39 $ 63.724  Millions$ 7.595  Millions
Rhythm Pharmaceuticals Inc   8.24 $ 333.288  Millions$ 40.465  Millions
Neubase Therapeutics inc   8.23 $ 17.660  Millions$ 2.145  Millions
Oragenics Inc   8.21 $ 11.427  Millions$ 1.392  Millions

Date modified: 2026-09-08T15:10:53+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.